🔥 Wednesday 15 April 2026 Wed, 15 Apr 2026

New Hope Corporation is raising A$300 million through a new convertible notes issue while simultaneously seeking to repurchase its existing A$300 million notes. The move coincides with elevated thermal coal prices amid Middle East tensions and ongoing operational guidance.

Mamba Exploration has secured a 70% stake in the Meeka East Gold Project following a $2 million placement and completed a major soil sampling program, setting the stage for a maiden drilling campaign pending assay results and approvals.

Noronex completed maiden drilling programs at key uranium and copper projects while bolstering its cash position through strategic asset sales. The company also formalised a 51% stake in its Etango North uranium project and navigates a CEO transition.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing of its investigational drug PYC-001 for Autosomal Dominant Optic Atrophy from single to multiple doses, marking a key step in its clinical development.

Asara Resources (ASX:AS1) is pushing ahead at its Kada Gold Project in Guinea’s prolific Siguiri Basin, boasting a 923,000-ounce gold resource and launching expansive 2026 drilling campaigns aimed at significantly growing both Indicated and Inferred categories.

QEM Limited is set to acquire two past-producing critical mineral projects in Idaho, backed by a $2.645 million placement. The move aligns with US efforts to secure domestic supplies of fluorspar, tungsten, and niobium amid global supply chain vulnerabilities.

Scott Technology delivered a solid HY26 with 7% EBITDA growth to $13 million, driven by strong performances in Materials Handling and Mining, offsetting softness in Protein and Appliances. Forward work rose to $177 million, underpinning expectations for a stronger second half despite geopolitical uncertainties.

Marquee Resources (ASX:MQR) has secured a non-exclusive R&D patent licence with Oak Ridge National Laboratory, granting access to NEAREST technology tailored for clay-rich rare earth deposits like Redlings in WA. This partnership could reshape processing efficiency and environmental impact for Marquee’s significant inferred resource.

ReNerve has moved its NervAlign Nerve Guide Matrix into stage 3 of commercial development, a key step toward FDA submission and eventual market entry. This progress supports the company’s ambition to provide surgeons with an alternative to donor nerves for repairing severe peripheral nerve injuries.

Omnia Metals has made a decisive entry into the US critical minerals market by acquiring the Stibnite Ridge antimony and silver project and staking the Radix rare earth and gallium project in Montana, backed by a $1.5 million capital raise.

Charger Metals has confirmed significant extensions to spodumene mineralisation at its Medcalf project, with drilling pushing lithium-bearing pegmatites to 600-700m depth and along strike. The company anticipates a substantial resource upgrade following assay results due in the coming weeks.

AuMEGA Metals has closed a C$30.1 million financing round, bolstering its institutional shareholder base and fully funding an expanded 2026 exploration program across its Newfoundland projects.

Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

Riversgold Limited has reported standout assay results from 31 drill holes at its Northern Zone Gold Project, including a spectacular 71 g/t gold intercept. The campaign expands the shallow gold mineralisation footprint, supporting imminent mining lease conversion and a funding agreement with MEGA Resources.

Larvotto Resources is progressing the Hillgrove Antimony-Gold Project on time and budget, aiming for mid-2026 production amid rising strategic demand for antimony. The project benefits from grid power, ongoing drilling success, and government support for critical minerals.

WhiteHawk Limited has raised A$1.5 million through a share placement to fund integration and growth of its newly acquired Quixxi Clarity AI platform, marking a strategic push into the AI governance market.

Magnum Mining names Antonio Vitor Junior as Managing Director to spearhead major drilling campaigns at its Azimuth and Parker projects, aiming to convert promising early rare earth results into a formal resource.

Strategic Energy Resources has locked in a binding joint venture with Sumitomo Metal Mining Oceania to explore its Bulimba Gold Project in northeast Queensland, with Sumitomo able to earn up to 90% through staged commitments over five years.

EV Resources has confirmed a large-scale, shallow carbonate replacement deposit (CRD) antimony system at its Los Lirios project in Mexico, with 10 of 11 drill holes intersecting the mineralised limestone unit. The system extends over a 400m strike and remains open in multiple directions, advancing the company towards a maiden JORC resource estimate.

Iceni Gold’s initial RC drilling at Goose Well confirms historic gold mineralisation and reveals a major fault structure that could unlock broader potential. Diamond drilling is set to refine the geological picture and target high-grade shoots.

Wildcat Resources (ASX: WC8) has expanded its Bolt Cutter Central lithium discovery footprint beyond 2.3km with multiple high-grade spodumene intercepts, while advancing the Definitive Feasibility Study for its Tabba Tabba Project. The company maintains a strong cash position of A$43.3 million as it prepares for further drilling and development milestones.

Orthocell has secured approval for its Remplir™ nerve repair device to be used across 221 U.S. military and veterans hospitals, marking a major step in its U.S. commercial expansion. The approval follows clinical validation in conflict zones, positioning Orthocell to deepen penetration into defence healthcare.

Duratec's joint venture with Ertech has clinched a $281 million contract to upgrade submarine infrastructure at HMAS Stirling, marking a major step in Australia's AUKUS defence preparations.